Literature DB >> 22551697

Decreased bone mineralization in children with Noonan syndrome: another consequence of dysregulated RAS MAPKinase pathway?

Kiran S Choudhry1, Monica Grover, Alyssa A Tran, E O'Brian Smith, Kenneth J Ellis, Brendan H Lee.   

Abstract

INTRODUCTION: Noonan syndrome (NS) is a disorder of RAS- mitogen activated protein kinase (MAPK) pathway with clinical features of skeletal dysplasia. This pathway is essential for regulation of cell differentiation and growth including bone homeostasis. Currently, limited information exists regarding bone mineralization in NS.
MATERIALS AND METHODS: Using dual-energy X-ray absorptiometry (DXA), bone mineralization was evaluated in 12 subjects (mean age 8.7 years) with clinical features of NS. All subjects underwent genetic testing which showed mutations in PTPN11 gene (N=8) and SOS1 gene (N=1). In a subgroup of subjects with low bone mass, indices of calcium-phosphate metabolism and bone turnover were obtained.
RESULTS: 50% of subjects had low bone mass as measured by DXA. Z-scores for bone mineral content (BMC) were calculated based on age, gender, height, and ethnicity. Mean BMC z-score was marginally decreased at -0.89 {95% CI -2.01 to 0.23; p=0.1}. Mean total body bone mineral density (BMD) z-score was significantly reduced at -1.87 {95% CI -2.73 to -1.0; p=0.001}. Mean height percentile was close to - 2 SD for this cohort, thus total body BMD z-scores were recalculated, adjusting for height age. Adjusted mean total body BMD z-score was less reduced but still significant at -0.82 {95% CI -1.39 to -0.25; p=0.009}. Biochemical evaluation for bone turnover was unremarkable except serum IGF-I and IGF-BP3 levels which were low-normal for age. DISCUSSION: Children with NS have a significantly lower total body BMD compared to age, gender, ethnicity and height matched controls. In addition, total BMC appears to trend lower in children with NS compared to controls. We conclude that the metabolic bone disease present resulted from a subtle variation in the interplay of osteoclast and osteoblast activity, without clear abnormalities being defined in the metabolism of either. Clinical significance of this finding needs to be validated by larger longitudinal studies. Also, histomorphometric analysis of bone tissue from NS patients and mouse model of NS may further elucidate the relationship between the RAS-MAPK pathway and skeletal homeostasis.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22551697      PMCID: PMC3356458          DOI: 10.1016/j.ymgme.2012.04.003

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  32 in total

1.  Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions.

Authors:  Feng-Chun Yang; Shi Chen; Alexander G Robling; Xijie Yu; Todd D Nebesio; Jincheng Yan; Trent Morgan; Xiaohong Li; Jin Yuan; Janet Hock; David A Ingram; D Wade Clapp
Journal:  J Clin Invest       Date:  2006-10-19       Impact factor: 14.808

2.  Costello syndrome: clinical diagnosis in the first year of life.

Authors:  M Cristina Digilio; Anna Sarkozy; Rossella Capolino; M Beatrice Chiarini Testa; Giorgia Esposito; Andrea de Zorzi; Renato Cutrera; Bruno Marino; Bruno Dallapiccola
Journal:  Eur J Pediatr       Date:  2007-08-29       Impact factor: 3.183

3.  Bone metabolism markers and bone mineral density in children with neurofibromatosis type-1.

Authors:  Ozgur Duman; Sebahat Ozdem; Doga Turkkahraman; Nihal Dundar Olgac; Firat Gungor; Senay Haspolat
Journal:  Brain Dev       Date:  2008-03-24       Impact factor: 1.961

4.  SOS1 is the second most common Noonan gene but plays no major role in cardio-facio-cutaneous syndrome.

Authors:  Martin Zenker; Denise Horn; Dagmar Wieczorek; Judith Allanson; Silke Pauli; Ineke van der Burgt; Helmuth-Guenther Doerr; Harald Gaspar; Michael Hofbeck; Gabriele Gillessen-Kaesbach; Andreas Koch; Peter Meinecke; Stefan Mundlos; Anja Nowka; Anita Rauch; Silke Reif; Christian von Schnakenburg; Heide Seidel; Lars-Erik Wehner; Christiane Zweier; Susanne Bauhuber; Verena Matejas; Christian P Kratz; Christoph Thomas; Kerstin Kutsche
Journal:  J Med Genet       Date:  2007-06-23       Impact factor: 6.318

5.  Germline KRAS mutations cause Noonan syndrome.

Authors:  Suzanne Schubbert; Martin Zenker; Sara L Rowe; Silke Böll; Cornelia Klein; Gideon Bollag; Ineke van der Burgt; Luciana Musante; Vera Kalscheuer; Lars-Erik Wehner; Hoa Nguyen; Brian West; Kam Y J Zhang; Erik Sistermans; Anita Rauch; Charlotte M Niemeyer; Kevin Shannon; Christian P Kratz
Journal:  Nat Genet       Date:  2006-02-12       Impact factor: 38.330

6.  Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1).

Authors:  T Tucker; C Schnabel; M Hartmann; R E Friedrich; I Frieling; H-P Kruse; V-F Mautner; J M Friedman
Journal:  J Med Genet       Date:  2008-12-09       Impact factor: 6.318

7.  High bone turnover and accumulation of osteoid in patients with neurofibromatosis 1.

Authors:  S Seitz; C Schnabel; B Busse; H U Schmidt; F T Beil; R E Friedrich; T Schinke; V F Mautner; M Amling
Journal:  Osteoporos Int       Date:  2009-05-05       Impact factor: 4.507

Review 8.  Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction.

Authors:  Bruce D Gelb; Marco Tartaglia
Journal:  Hum Mol Genet       Date:  2006-10-15       Impact factor: 6.150

9.  Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype.

Authors:  Claudio Carta; Francesca Pantaleoni; Gianfranco Bocchinfuso; Lorenzo Stella; Isabella Vasta; Anna Sarkozy; Cristina Digilio; Antonio Palleschi; Antonio Pizzuti; Paola Grammatico; Giuseppe Zampino; Bruno Dallapiccola; Bruce D Gelb; Marco Tartaglia
Journal:  Am J Hum Genet       Date:  2006-05-01       Impact factor: 11.025

10.  Generalized metabolic bone disease in Neurofibromatosis type I.

Authors:  Nicola Brunetti-Pierri; Stephen B Doty; John Hicks; Kelly Phan; Roberto Mendoza-Londono; Maria Blazo; Alyssa Tran; Susan Carter; Richard Alan Lewis; Sharon E Plon; William A Phillips; E O'Brian Smith; Kenneth J Ellis; Brendan Lee
Journal:  Mol Genet Metab       Date:  2008-03-04       Impact factor: 4.797

View more
  5 in total

Review 1.  When Low Bone Mineral Density and Fractures Is Not Osteoporosis.

Authors:  Smita Jha; Marquis Chapman; Kelly Roszko
Journal:  Curr Osteoporos Rep       Date:  2019-10       Impact factor: 5.096

2.  Deletion of SHP-2 in mesenchymal stem cells causes growth retardation, limb and chest deformity, and calvarial defects in mice.

Authors:  Philip E Lapinski; Melissa F Meyer; Gen-Sheng Feng; Nobuhiro Kamiya; Philip D King
Journal:  Dis Model Mech       Date:  2013-09-25       Impact factor: 5.758

Review 3.  Protein tyrosine phosphatases in skeletal development and diseases.

Authors:  Huiliang Yang; Lijun Wang; Christian Shigley; Wentian Yang
Journal:  Bone Res       Date:  2022-01-28       Impact factor: 13.567

4.  Biphasic regulation of osteoblast development via the ERK MAPK-mTOR pathway.

Authors:  Jung-Min Kim; Yeon-Suk Yang; Jaehyoung Hong; Sachin Chaugule; Hyonho Chun; Marjolein C H van der Meulen; Ren Xu; Matthew B Greenblatt; Jae-Hyuck Shim
Journal:  Elife       Date:  2022-08-17       Impact factor: 8.713

5.  The Extracellular Signal-Regulated Kinase Mitogen-Activated Protein Kinase Pathway in Osteoblasts.

Authors:  Matthew B Greenblatt; Jae-Hyuck Shim; Seoyeon Bok; Jung-Min Kim
Journal:  J Bone Metab       Date:  2022-02-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.